Skip to main content
. 2017 Oct 23;6(10):e390. doi: 10.1038/oncsis.2017.88

Figure 5.

Figure 5

Methyl DNA-binding protein MBD2 deposition at genes modulated by CAF-secreted factors. (a) Western blot analysis of MBD2 proteins in SKBR3 and AU565 cells treated with siRNA targeting MBD2. (b) Venn diagram of genes upregulated by CAF-CMs compared with genes upregulated by MBD2 siRNA (P<0.0001, hypergeometric test). (c) Linear regression curve presenting the relationship between the fold change in gene expression induced by CAF-CMs and siRNA targeting MBD2 in SKBR3 and (d) in AU565. (e) Chromatin immunoprecipitation mapping MBD2-biding sites at the 5’ end regions of genes upregulated by CAF-secreted factors in SKBR3 and (f) in AU565. (*P<0.05; **P<0.01; ****P<0.0001, two-tailed unpaired Student’s t-test. Error bars=s.e.m). (g) Chromatin immunoprecipitation assays of MBD2 enrichment at the 5’ end regions of genes upregulated by CAF-secreted factors in SKBR3 treated with CAF-8-CM (CAF-CM), NT (not treated); and (h) in AU565. (*P<0.05; **P<0.01; ****P<0.0001, two-tailed unpaired Student’s t-test. Error bars=s.e.m).